Helping bring transformative therapies to market

The success of mRNA vaccines in response to COVID-19 catalyzed a new era in vaccines and re-ignited interest in nucleic acid therapies. A heightened threat of new pandemics and antimicrobial resistance means the world is looking to biopharma for solutions to these global problems – and to enable the acceleration of those solutions into manufacturing.

After decades of promise, cell and gene therapies are becoming real options for patients, from curing previously deadly blood cancers with CAR-T therapies to using approved gene therapies to treat diseases like sickle cell anemia. Cytiva is developing new platforms that will help take these solutions to patients’ bedsides.

The boom in artificial intelligence is accelerating therapeutic development from design through to manufacturing. As these new tools become central to the next generation of clinical translation workflows, Cytiva is working to ensure that manufacturing development keeps pace through its own digitization journey.

With four major research and development hubs in Sweden, the United States, Switzerland, and the United Kingdom – and training, collaboration and innovation centers in 10 locations worldwide – Cytiva provides rapid support for a range of our customers’ needs, from fundamental biological research to developing new diagnostics, vaccines, biologic drugs, and novel cell and gene therapies.  

We partner with both private and public institutions to solve key technical challenges and drive the industrialization of cell and gene therapies. Our partnerships include the Centre for Advanced Therapeutic Cell Technologies in partnership with the Canadian government, the Sefia™ cell therapy manufacturing platform in collaboration with Kite, a Gilead Company, and the Testa Center, a shared initiative with the Swedish government.
 

From improving process control to supporting new modes of therapeutic delivery and transforming the footprint of our bioprocessing equipment, we never rest while supporting our customers’ journeys into the next phase of bioprocessing.

We bring scientists together to help solve major industry challenges with our expertise and support. The Testa Challenge, our internal Innovation Accelerator and BioChallenge each encourage participation and collaboration from our global community and reveal powerful new possibilities for the future of biomanufacturing.

Our approach to sustainability is driven by collaboration across the entire value chain – from our associates and suppliers to customers and patients. Together, we are committed to reducing our carbon footprint, using water responsibly, evolving our use of plastics, rethinking packaging, driving community impact and increasing diversity and inclusion.